1,314
Views
12
CrossRef citations to date
0
Altmetric
Commentary

Breaking the cycle of opioid use disorder with Ibogaine

, PhD

References

  • Fernandez JW, Fernandez RL. “Returning to the path”: the use of iboga[ine] in an equatorial African ritual context and the binding of time, space, and social relationships. Alkaloids Chem Biol. 2001;56:235–47.
  • Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115:9–24. doi:10.1016/j.jep.2007.08.034.
  • Baumann MH, Rothman RB, Pablo JP, Mash DC. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther. 2001;297:531–39.
  • Mash DC, Ameer B, Prou D, Howes JF, Maillet EL. Oral noribogaine shows high brain uptake and antiwithdrawal effects not associated with place preference in rodents. J Psychopharmacol. 2016;30:688–97. doi:10.1177/0269881116641331.
  • Belgers M, Leenaars M, Homberg JR, Riskes-Hoitinga M, Schellekens A, Hooijmans CR. Ibogaine and addiction in the animal model: a systematic review and meta-analysis. Transl Psychiatry. 2016;6:e826. doi:10.1038/tp.2016.71.
  • Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, Sanchez-Ramos J. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci. 1998;844:274–92. doi:10.1111/j.1749-6632.1998.tb08242.x.
  • Vastag B Addiction research. Ibogaine therapy: a “vast, uncontrolled experiment”. Science. 2005;308:345–46. doi:10.1126/science.308.5720.345.
  • Brown KT, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44:24–36. doi:10.1080/00952990.2017.1320802.
  • Noller GE, Framptom CM, Yazar-Klosinski BY. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44:37–46. doi:10.1080/00952990.2017.1310218.
  • Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, Kamlet JD, Hearn WL. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155–71.
  • Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, Singleton EG. Mayor M Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000;914:394–401. doi:10.1111/j.1749-6632.2000.tb05213.x.
  • Hearn WL, Pablo J, Hime GW, Mash DC. Identification and quantitation of ibogaine and an O-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry. J Anal Toxicol. 1995;19:427–34. doi:10.1093/jat/19.6.427.
  • Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57:398–412. doi:10.1111/j.1556-4029.2011.02008.x.
  • Curtis S. Florence, Chao Zhou, Feijun Luo, Likang Xu. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Medical Care, 2016; 54 (10): 901 DOI:10.1097/MLR.0000000000000625
  • Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:1445–1452. DOI:10.15585/mmwr.mm655051e1

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.